TIDMINC

RNS Number : 8072V

Incanthera PLC

19 April 2021

19 April 2021

Incanthera plc

("Incanthera" or the "Company")

Directors dealings

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the "Transactions").

The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:

Employee Company Position Transaction Volume Purchase Price

Tim McCarthy Chairman 49,382 13.50p

Simon Ward CEO 51,593 13.50p

   Pawel Zolnierzyck             COO                                                        11,307 

13.20p

Laura Brogden CFO 15,057 13.15p

Suzanne Brocks Head of Communications 50,000 13.00p

Total Shareholdings following the Transactions:

Employee Company Position Total Shareholding % of Share Capital

Tim McCarthy Chairman 3,931,646 5.31%

Simon Ward CEO 2,704,199 3.65%

   Pawel Zolnierzyck             COO                                                        669,544 

0.90%

Laura Brogden CFO 46,034 0.06%

   Suzanne Brocks                 Head of Communications                   325,594 0.44% 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which

forms part of domestic   UK   law pursuant to the European Union (Withdrawal) Act 2018). 

For further enquiries:

 
Incanthera plc 
 www.incanthera.com 
 
 Tim McCarthy, Chairman 
 tim.mccarthy@incanthera.com                   +44 (0) 7831 675747 
 
 Simon Ward, Chief Executive Officer 
 simon.ward@incanthera.com                     +44 (0) 7747 625506 
 
 Suzanne Brocks, Head of Communications 
 suzanne.brocks@incanthera.com                 +44 (0) 7776 234600 
 
Aquis Exchange Corporate Adviser: 
 Cairn Financial Advisers LLP 
 Jo Turner/James Lewis/Mark Rogers            +44 (0) 20 7213 0880 
 
Broker: 
 Stanford Capital Partners Ltd 
 Patrick Claridge/Tom Price/John Howes/Bob 
 Pountney                                     +44 (0) 20 3815 8880 
 

Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities/ person closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
       Name 
                                               1. Tim McCarthy        Chairman 
                                               2. Simon Ward          CEO 
                                               3. Pawel Zolnierczyk   PDMR 
                                               4. Laura Brogden       PDMR 
                                               5. Suzanne Brocks      PDMR 
     -------------------------------  ---------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/status                  As above 
     -------------------------------  ---------------------------------------- 
 b)   Initial notification/Amendment   Initial Notification 
     -------------------------------  ---------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                             Incanthera plc 
     -------------------------------  ---------------------------------------- 
 b)   LEI                              2138002HEV4UFBOEXQ97 
     -------------------------------  ---------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------- 
 a)   Description of the financial     Ordinary Shares of 0.02p 
       instrument 
     -------------------------------  ---------------------------------------- 
 b)   Identification code              GB00BGL7YW15 
     -------------------------------  ---------------------------------------- 
 c)   Nature of the transactions       Purchase of Ordinary Shares 
     -------------------------------  ---------------------------------------- 
 d)   Volumes and Prices                     Volume       Price 
                                               1. 49,382   13.50p 
                                                          ------- 
                                               2. 51,593   13.50p 
                                                          ------- 
                                               3. 11,307   13.20p 
                                                          ------- 
                                               4. 15,057   13.15p 
                                                          ------- 
                                               5. 50,000   13.00p 
                                                          ------- 
     -------------------------------  ---------------------------------------- 
 e)   Aggregated information             Volume    Prices 
       - Aggregated volume                177,339   13.00-13.50p 
       - Price                                     ------------- 
     -------------------------------  ---------------------------------------- 
 f)   Date of the transactions         15 April 2021 
     -------------------------------  ---------------------------------------- 
 f)   Place of the transactions        AQSE Growth Market, UK 
     -------------------------------  ---------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXDKFBPFBKDFQD

(END) Dow Jones Newswires

April 19, 2021 02:00 ET (06:00 GMT)

Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Incanthera
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Incanthera